Skip to main content
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. — Investor Relations & Filings

Ticker · DSGN ISIN · US25056L1035 US Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US DSGN

About Design Therapeutics, Inc.

https://www.designtx.com/

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 91% confidence The document is a United States SEC Form 8-K “Current Report” filed under Item 8.01 Other Events, announcing clinical trial data and forward-looking statements. It is an SEC regulatory filing rather than a full report (e.g., 10-K, earnings release) and is not simply reporting voting results or management changes. Therefore it belongs to the general Regulatory Filings category (RNS).
2026-05-18 English
DEF 14A - Design Therapeutics, Inc. (0001807120) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
ARS - Design Therapeutics, Inc. (0001807120) (Filer)
Annual Report
2026-04-23 English
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2026, reporting the appointment of a new director, David Shapiro, M.D., to the Board of Directors. It details his compensation and committee assignment. The content focuses on changes in the company's board and management. There are no financial statements or earnings data, so it is not an Annual Report, Earnings Release, or Interim Report. The document is not a proxy solicitation or voting results announcement. It clearly fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors.
2026-04-01 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 29, 2026. The key content is the resignation of a board member, Deepa Prasad, effective February 1, 2026, due to conflict-avoidance policies related to a new role. This is a clear announcement of a change in the company's board of directors. There is no financial data or report attached, nor is this a report publication announcement. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2026-01-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.